Core Insights - Twist Bioscience Corporation reported a first-quarter 2026 loss of 50 cents per share, aligning with Wall Street expectations, while sales reached $103.70 million, a 17% year-over-year increase, surpassing both consensus and management guidance [1][4] Financial Performance - The adjusted EBITDA loss for the quarter was $13.4 million, an improvement from a loss of $16.3 million in the previous year [1][2] - Gross margin for the first quarter of fiscal 2026 increased to 52%, up from 48.3% a year ago [2] - The company had approximately $198 million in cash, cash equivalents, and short-term investments as of December 31, 2025 [3] Customer and Product Metrics - Twist shipped products to approximately 2,538 customers in Q1 2026, an increase from about 2,376 customers a year ago [2] - The company shipped approximately 271,000 genes in the quarter, compared to around 205,000 genes in the same period last year [2] Future Outlook - Twist Bioscience raised its fiscal 2026 sales guidance to $435 million-$440 million, compared to the previous range of $425 million-$435 million, with expectations for revenue growth balanced across DSPS and NGS [4] - The company anticipates gross margin to remain above 52% for fiscal 2026 and aims for adjusted EBITDA breakeven in Q4 of fiscal 2026 [4] Analyst Commentary - Analysts express confidence in the long-term revenue growth trajectory of the company, highlighting its aggressive investments in multiple markets that could lead to over 20% growth [6] - The company's strategy to moderate investments while scaling into the FOTF is viewed positively, as it may broaden the appeal of the company's story if executed effectively [6][7]

Core Insights - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare sectors, highlighting key trends and catalysts that influence market valuations [1] Group 1 - The newsletter is led by a biotech consultant with over 5 years of experience covering the industry and has compiled detailed reports on more than 1,000 companies [1] - The investing group, Haggerston BioHealth, caters to both novice and experienced biotech investors, providing insights on catalysts, buy and sell ratings, and forecasts for major pharmaceutical companies [1] - The group offers integrated financial statements, discounted cash flow analysis, and market-by-market analysis to aid investors in making informed decisions [1]

Core Insights - Twist Bioscience reported a strong first-quarter performance for fiscal 2026, with revenue reaching $103.7 million, reflecting a 17% year-over-year growth and marking the 12th consecutive quarter of revenue growth [5][4]. - The growth was significantly driven by demand for AI-enabled discovery, with over $25 million in orders specifically tied to this area booked for fiscal 2025 [1][5]. - The company aims for adjusted EBITDA break-even by the fourth quarter of fiscal 2026, while also increasing operating expenses to support growth [13][5]. Financial Performance - DNA synthesis and protein solutions (DSPS) revenue increased to $51.1 million, up 27% year-over-year [1]. - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million compared to the prior-year quarter [3]. - Gross margin was reported at 52.0%, higher than expected, attributed to revenue growth and process improvements [4]. Market Trends - The company is expanding its services beyond DNA synthesis to include protein expression and antibody characterization, targeting large pharma, tech companies, and well-funded biotechs [6]. - NGS applications revenue was approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [7]. - Therapeutics revenue increased to approximately $37.2 million, up 39% year-over-year, driven by greater uptake from large pharma and biotech [15]. Guidance and Outlook - Twist raised its full-year revenue outlook to $435 million to $440 million, indicating about 16% growth at the midpoint [12]. - For the second quarter, the company expects revenue of $107 million to $108 million, also reflecting about 16% growth at the midpoint [12]. - Management expressed confidence in continued growth in NGS driven by key accounts and partnerships [9][10]. Geographic and Sector Performance - Revenue by geography showed growth in the Americas ($58.4 million), EMEA ($38.4 million), and APAC ($7.0 million) compared to the previous year [11]. - Global supply partner revenue rose to $12.8 million, a 50% increase, attributed to new partnerships and growth among diagnostics OEM partners [11]. - Academic research and government revenue remained flat at approximately $12.2 million, with expectations for growth in the second quarter due to increased confidence in NIH funding [15].

Core Viewpoint - The U.S. stock market is showing resilience with major indexes rebounding from earlier declines, driven by sector strength and cautious optimism as investors navigate corporate news and economic events [1][14]. Major Index Performance and Midday Momentum - The S&P 500 has increased by 0.5%, breaking a three-day losing streak, while the Dow Jones Industrial Average is up 317 points (0.6%) and the Nasdaq Composite has climbed 0.6% [2]. - The market's recovery is broad-based, with specific strength in sectors such as computer storage, airlines, and cruise-ship operators, benefiting from easing crude oil prices [3]. Upcoming Market Events and Economic Outlook - A busy week ahead includes major technology earnings reports from companies like Amazon, Alphabet, Palantir, and AMD, which will be critical for market sentiment regarding the tech sector and AI investments [4]. - Key economic data, including the January employment report and the ISM Report on Business Manufacturing PMI, are anticipated, alongside a hawkish stance from the Federal Reserve, which maintained its federal funds rate at 3.5-3.75% [5]. Major Stock News and Corporate Developments - Oracle shares are up 2% after announcing plans to raise up to $50 billion in 2026 to expand its AI infrastructure capacity, driven by strong demand from major clients [6]. - Walt Disney's stock is down 6% despite beating fiscal first-quarter earnings and revenue estimates, attributed to higher costs impacting net profit [7]. - Nvidia shares declined 1.1% following reports that its commitment to invest $100 billion in OpenAI was not a firm commitment [8]. - Microsoft shares are down 1%, while Snowflake initially traded lower but gained 1.5% after announcing a $200 million deal with OpenAI [9]. - Twist Bioscience shares rose 7% after raising its FY2026 revenue outlook, while GameStop surged 6% amid speculation regarding merger plans [10]. Commodity Market Dynamics - Crude oil prices fell nearly 5%, trading over $3 per barrel lower, due to easing geopolitical tensions following comments from President Trump regarding Iran [12]. - Precious metals experienced volatility, with gold briefly dropping below $4,500 per ounce before stabilizing, while silver saw significant swings [13].

分组1 - Twist Bioscience reported a quarterly loss of $0.5 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.48, and an improvement from a loss of $0.53 per share a year ago, indicating a surprise of -5.26% [1] - The company generated revenues of $103.7 million for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.05%, but showing growth from $88.71 million in the same quarter last year [2] - Over the last four quarters, Twist Bioscience has surpassed consensus revenue estimates three times, but only once for EPS estimates [2] 分组2 - The stock has increased by approximately 29.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at -$0.46 for the coming quarter and -$1.64 for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Twist Bioscience belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Financial Data and Key Metrics Changes - Revenue for Q1 increased to $103.7 million, representing a growth of 17% year-over-year and approximately 5% sequentially [21] - Gross margin improved to 52.0%, an increase of approximately four margin points compared to Q1 of Fiscal 2025 [21][25] - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million versus Q1 of Fiscal 2025 [25] Business Line Data and Key Metrics Changes - DNA synthesis and protein solutions revenue rose to $51.1 million, a growth of 27% year-over-year, driven by demand from customers pursuing AI-enabled discovery [21] - NGS applications revenue grew to approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [21] - Revenue from therapeutics increased to approximately $37.2 million, reflecting a 39% increase year-over-year [22] Market Data and Key Metrics Changes - Americas revenue increased to approximately $58.4 million, a growth of 9% year-over-year [22] - AMEA revenue rose to approximately $38.4 million, a growth of 36% year-over-year [22] - Global supply partner revenue increased by 50% to $12.8 million, driven by new partnerships and growth in diagnostics OEM partners [24] Company Strategy and Development Direction - The company aims to leverage its semiconductor-based DNA synthesis platform to enhance speed, scale, quality, and affordability for customers [6] - The estimated serviceable market has expanded from approximately $2 billion in 2020 to roughly $7 billion today, with expectations to exceed $12 billion by 2030 [8] - The company is focused on disciplined product innovation and expanding its addressable markets while maintaining margin discipline and capital efficiency [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reaching Adjusted EBITDA break-even by Q4 of Fiscal 2026, supported by consistent revenue growth and disciplined investment in operating expenses [29][30] - The company is well-positioned to capitalize on the growing demand for AI-enabled drug discovery and precision diagnostics [30] - Management noted that the growth is driven by a repeatable model and operational execution that scales efficiently [28] Other Important Information - The company plans to host an investor day in May to provide deeper insights into its strategy, product roadmap, and market expansion opportunities [30] - The company has made targeted investments in commercial teams and digital infrastructure to support growth [11][52] Q&A Session Summary Question: Demand for AI-driven discovery and its duration - Management noted that demand is expected to be durable, with customers returning for larger orders and the potential for AI to become the first pass in drug discovery [34] Question: Increased guidance confidence for DNA synthesis and NGS - Management indicated that confidence comes from overall strong performance across the board, with a specific customer dynamic in NGS applications having improved [39] Question: Gross margin expectations for Q2 and beyond - Management expects continued improvements in gross margin throughout the year, but at a moderated pace due to ongoing investments in capacity and automation [48] Question: Strategic investments made in the quarter - Investments were made in hiring sales and commercial personnel, as well as transient investments in digital infrastructure to enhance e-commerce capabilities [52] Question: New partnerships in the diagnostic space - Management is actively working on securing new partnerships for sustained growth in 2027 and beyond, while current growth in 2026 will primarily come from existing partners [58]

Financial Data and Key Metrics Changes - Revenue for Q1 increased to $103.7 million, representing a growth of 17% year-over-year and approximately 5% sequentially [21] - Gross margin improved to 52.0%, an increase of approximately four margin points compared to Q1 of fiscal 2025 [21][25] - Adjusted EBITDA loss was approximately $13.4 million, an improvement of approximately $2.8 million versus Q1 of fiscal 2025 [25] Business Line Data and Key Metrics Changes - DNA synthesis and protein solutions revenue increased to $51.1 million, a growth of 27% year-over-year, driven by demand from customers pursuing AI-enabled discovery [21] - NGS applications revenue grew to approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [21] - Revenue from therapeutics rose to approximately $37.2 million, reflecting a 39% increase year-over-year [22] Market Data and Key Metrics Changes - Americas revenue increased to approximately $58.4 million, a growth of 9% year-over-year [22] - EMEA revenue rose to approximately $38.4 million, a growth of 36% year-over-year [22] - Global supply partner revenue increased by 50% to $12.8 million, driven by new partnerships and growth in diagnostics OEM partners [24] Company Strategy and Development Direction - The company aims to leverage its semiconductor-based DNA synthesis platform to enhance speed, scale, quality, and affordability for customers [6] - The estimated serviceable market has expanded from approximately $2 billion in 2020 to roughly $7 billion today, with expectations to exceed $12 billion by 2030 [8] - The company is focused on disciplined product innovation and operational execution to support growth while maintaining margin discipline [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reaching adjusted EBITDA break-even by Q4 of fiscal 2026, supported by consistent revenue growth and disciplined investment in operating expenses [29][30] - The company is positioned as an enabling infrastructure provider across the biological continuum, from early discovery through diagnostics to therapeutics development [29] Other Important Information - The company plans to host an Investor Day in May to provide deeper insights into its strategy, product roadmap, and market expansion opportunities [30] - The company has made targeted investments in commercial teams and digital infrastructure to support growth [11][52] Q&A Session Summary Question: Demand for AI-driven discovery and its duration - Management noted that demand is expected to be durable, with customers returning for larger orders, indicating strong growth potential [34] Question: Increased guidance confidence for DNA synthesis and NGS - The increase in guidance is attributed to overall confidence across the board, with a specific customer dynamic in NGS applications having improved [39] Question: Gross margin expectations for Q2 and beyond - Management indicated that while gross margin improvements are expected, they will be moderated due to ongoing investments in capacity and infrastructure [48] Question: Strategic investments made in the quarter - Investments were made in hiring sales and commercial personnel, as well as transient investments in digital infrastructure to enhance e-commerce capabilities [52]

Financial Data and Key Metrics Changes - Revenue for Q1 increased to $103.7 million, representing a 17% year-over-year growth and approximately 5% sequentially [20] - Gross margin improved to 52.0%, an increase of approximately four margin points compared to Q1 of Fiscal 2025 [20][24] - Adjusted EBITDA loss was approximately $13.4 million, an improvement of about $2.8 million versus Q1 of Fiscal 2025 [24] Business Line Data and Key Metrics Changes - DNA synthesis and protein solutions revenue rose to $51.1 million, a 27% year-over-year increase driven by AI-enabled discovery [20] - NGS applications revenue grew to approximately $52.6 million, with an 18% year-over-year growth when excluding one large customer [20] - Revenue from therapeutics increased to approximately $37.2 million, reflecting a 39% year-over-year growth [21] Market Data and Key Metrics Changes - Americas revenue increased to approximately $58.4 million, a 9% year-over-year growth [21] - AMEA revenue rose to approximately $38.4 million, a 36% year-over-year increase [21] - APAC revenue increased to approximately $7 million, compared to $6.7 million in the same period of Fiscal 2025 [21] Company Strategy and Development Direction - The company aims to leverage its semiconductor-based DNA synthesis platform to enhance speed, scale, quality, and affordability for customers [5] - The estimated serviceable market has expanded from approximately $2 billion in 2020 to roughly $7 billion today, with a target of over $12 billion by 2030 [7][8] - The company is focused on disciplined product innovation and expanding its addressable markets while maintaining margin discipline [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in reaching Adjusted EBITDA break-even by Q4 of Fiscal 2026, supported by consistent revenue growth and disciplined investment in operating expenses [11][27] - The company sees a durable opportunity in AI-enabled discovery, with increasing orders from large pharma and biotech customers [31][49] - Management highlighted the importance of maintaining a scalable cost structure while investing in growth [12][27] Other Important Information - The company plans to host an investor day in May to provide deeper insights into its strategy, product roadmap, and market expansion opportunities [28] - The company ended the quarter with $197.9 million in cash, cash equivalents, and short-term investments [25] Q&A Session Summary Question: Demand for AI-driven discovery and its duration - Management noted that demand is expected to be durable, with customers returning for larger orders, indicating strong growth potential [31] Question: Increased guidance confidence for DNA synthesis and NGS - Management attributed increased confidence to overall strong performance across the board and the return of a previously mentioned customer [37] Question: Gross margin expectations for Q2 and beyond - Management indicated that while gross margin improvements are expected, investments in growth may moderate the pace of margin expansion [44][46] Question: Strategic investments made in the quarter - Management detailed structural investments in hiring sales personnel and transient investments in digital infrastructure to support growth [50][52] Question: New partnerships in the diagnostic space - Management confirmed that growth in NGS for FY 2026 will primarily come from existing partners, with new partnerships being crucial for sustained growth in 2027 and beyond [56]

Fiscal 2026 Q1 Financial Results F E B R U A R Y 2 0 2 6 Legal Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading "FY 2026 Guidance", statements regarding future growth and expans ...

Revenue Results - Twist Bioscience Corporation announced preliminary, unaudited revenue results for Q1 fiscal 2026, ending December 31, 2025[4]. - The revenue expectations are subject to change based on ongoing internal control, review, and audit procedures, indicating potential material differences from final financial statements[5]. - The press release detailing the preliminary revenue results is dated January 12, 2026, and is available as Exhibit 99.1[8].